Literature reports indicate that genetic variants, primarily in the enzymes thiopurine S-methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15), are associated with an increased risk of developing myelosuppression, conferring up to twice the risk [5]. The gene discussed is TPMT; the disease is myelosuppression.